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Abstract
Background: Native T1 may be a sensitive, contrast-free, non-invasive cardiovascular magnetic resonance (CMR)
marker of myocardial tissue changes in patients with pulmonary artery hypertension. However, the diagnostic and
prognostic value of native T1 mapping in this patient group has not been fully explored. The aim of this work was to
determine whether elevation of native T1 in myocardial tissue in pulmonary hypertension: (a) varies according to
pulmonary hypertension subtype; (b) has prognostic value and (c) is associated with ventricular function and interaction.
Methods: Data were retrospectively collected from a total of 490 consecutive patients during their clinical 1.5 T CMR
assessment at a pulmonary hypertension referral centre in 2015. Three hundred sixty-nine patients had pulmonary
hypertension [58 ± 15 years; 66% female], an additional 39 had pulmonary hypertension due to left heart disease [68 ±
13 years; 60% female], 82 patients did not have pulmonary hypertension [55 ± 18; 68% female]. Twenty five healthy
subjects were also recruited [58 ±4 years); 51% female]. T1 mapping was performed with a MOdified Look-Locker
Inversion Recovery (MOLLI) sequence. T1 prognostic value in patients with pulmonary arterial hypertension was assessed
using multivariate Cox proportional hazards regression analysis.
Results: Patients with pulmonary artery hypertension had elevated T1 in the right ventricular (RV) insertion point
(pulmonary hypertension patients: T1 = 1060 ± 90 ms; No pulmonary hypertension patients: T1 = 1020 ± 80 ms p < 0.001;
healthy subjects T1 = 940 ± 50 ms p < 0.001) with no significant difference between the major pulmonary hypertension
subtypes. The RV insertion point was the most successful T1 region for discriminating patients with pulmonary
hypertension from healthy subjects (area under the curve = 0.863) however it could not accurately discriminate between
patients with and without pulmonary hypertension (area under the curve = 0.654). T1 metrics did not contribute to
prediction of overall mortality (septal: p = 0.552; RV insertion point: p = 0.688; left ventricular free wall: p = 0.258). Systolic
interventricular septal angle was a significant predictor of T1 in patients with pulmonary hypertension (p < 0.001).
Conclusions: Elevated myocardial native T1 was found to a similar extent in pulmonary hypertension patient subgroups
and is independently associated with increased interventricular septal angle. Native T1 mapping may not be of additive
value in the diagnostic or prognostic evaluation of patients with pulmonary artery hypertension.
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Background
Myocardial tissue changes have been visualised in
patients with pulmonary hypertension using cardiovas-
cular magnetic resonance (CMR) T1 mapping, T2 map-
ping and late gadolinium enhancement (LGE) CMR.
Native myocardial changes measured using native T1
mapping have been shown across a range of cardiac dis-
eases in clinical subjects [1, 2]. It has been shown that in
patients with pulmonary artery hypertension (PAH) the
right ventricular (RV) insertion point T1 is elevated. Sev-
eral studies also found elevated T1 in the interventricu-
lar septum and, in one case, the left ventricular (LV) free
wall [3–7].
Patients with pulmonary hypertension have been
shown to have worse prognosis in the presence of myo-
cardial changes visualized by LGE at the RV insertion
point [8] and in the septal myocardium [9], although the
independent prognostic significance of the myocardial
tissue changes in pulmonary hypertension remains
unclear [10]. Elevated native T1 at the insertion point
occurs in a similar location and pattern to LGE. The
co-occurrence of LGE and elevated T1 implies that they
may have common mechanistic causes. However, studies
in both patients and animal models have reported higher
native T1 in the RV insertion points than in controls,
despite no LGE being seen in this region, which indi-
cates that native T1 may be a more sensitive marker of
myocardial changes than the presence of LGE [3, 11].
Therefore, T1 mapping may provide a contrast-free and
sensitive marker of myocardial tissue changes in pul-
monary artery hypertension, and there is reason to sus-
pect that T1 changes may have prognostic relevance.
Pulmonary hypertension is a heterogeneous condition
with 5 diagnostic subcategories: PAH; pulmonary hyper-
tension due to left heart disease pulmonary hypertension
due to lung disease and/or hypoxia; chronic thrombo-
embolic pulmonary hypertension (CTEPH) and pulmon-
ary hypertension with unclear or multifactorial causes.
To date T1 mapping studies have been performed in
relatively small populations, with only one report
wherein diagnostic subcategories were considered separ-
ately [4] and therefore it is unclear whether myocardial
T1 changes in patients with pulmonary hypertension are
homogeneous across patient subtypes.
RV remodelling and failure occur as a result of pro-
longed elevations of RV afterload. Elevated mean pul-
monary artery pressure (PAP) and pulmonary vascular
resistance (PVR) are characteristic features of the condi-
tion, however it is the failure of the RV that is the key
determinant of adverse outcome [9, 12–16]. Early
markers of adverse cardiac remodelling may be able to
guide treatment strategies, predicting therapy response
and failure. It is unclear whether elevated myocardial T1
is associated with prognostic features in pulmonary
hypertension, and whether it can provide additive infor-
mation to patient outcome.
In this work, we sought to determine whether eleva-
tion of the native T1 in myocardial tissue in pulmonary
hypertension: (a) varies according to pulmonary hyper-
tension subtype; (b) is related to adverse outcome inde-
pendent of RV size and function, and (c) is associated
with biventricular remodeling and function.
Methods
Subjects
Approval for analysis of imaging data was granted by the
local research ethics committee and consent was waived
for this retrospective database study. Consecutive
patients with suspected pulmonary hypertension under-
went CMR including a modified Look-Locker inversion
recovery (MOLLI) sequence as part of their clinical
assessment at a tertiary pulmonary hypertension referral
centre between 01.01.2015 and 31.12.2015. Exclusion
criteria were applied to all subjects according to stand-
ard criteria for undergoing CMR. A total of 490 patients
were identified. Three hundred sixty-nine patients had a
diagnosis of pulmonary hypertension without left heart
disease as specified below, 39 patients were identified
with pulmonary hypertension associated with left heart
disease, and 82 did not have a diagnosis of pulmonary
hypertension - mean PAP < 25 mmHg – and were used
as a control group, see Fig. 1. Twenty five age matched
healthy subjects with no current cardiac or respiratory
symptoms and no history of cardiac disorders were also
recruited as an additional control group. Patients with a
mean PAP ≥ 25 mmHg and pulmonary capillary wedge
pressure (PCWP) > 15 mmHg were considered to have a
diagnosis of pulmonary hypertension due to left heart
disease, and patients with a mean PAP < 25 mmHg were
considered to have a diagnosis of no pulmonary hyper-
tension. Subtypes of pulmonary hypertension were
defined as previously described [17].
The patients with pulmonary hypertension included the
following sub-group diagnoses: Group 1 pulmonary arterial
hypertension; Idiopathic PAH, n = 83; PAH heritable, n = 5;
PAH associated with connective tissue disease (PAH-CTD),
n = 89; PAH associated with congenital heart disease
(CHD), n = 31; PAH associated with portal hypertension, n
= 9; PAH drug/toxin induced, n = 3; PAH other, n = 3.
Group 2 left heart disease, n = 39 (note these patients were
considered separately – see Fig. 1). Group 3 PH associated
with lung disease, n = 41. Group 4, CTEPH n = 92; group 5,
sarcoidosis, n = 10; patients without diagnosis: 3.
All patients with PAH (n = 223) were treated with
PAH therapy. Patients with PAH were strictly defined
for this study as PCWP < 16 and no evidence of lung
disease or left heart disease. Chronic thromboembolic
pulmonary hypertension (CTEPH) patients and some
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aetiologies of Group 5 pulmonary hypertension were
treated as appropriate. Patients with left heart disease
were divided into two groups, firstly typical left heart
disease (n = 35) and secondly, PAH with left heart dis-
ease comorbidity (n = 4). Patients in the PAH associated
with lung disease were divided into severe PAH-lung
disease (n = 13) and PAH with non-severe lung disease
comorbidity (n = 28). A summary of all subject charac-
teristics is shown in Table 1, and a detailed breakdown
of the subgroups provided in Additional file 1: Table S1.
Right heart catheterisation
All patients underwent right heart catheterisation. Right
heart catheterisation was performed by a using a
balloon-tipped 7.5 Fr thermodilution catheter (Becton-
Dickinson, Franklin Lakes, New Jersey, USA), typically
via the internal jugular vein using a Swan-Ganz catheter.
PVR index (PVRI) was defined as (mPAP-PCWP)/CI,
where CI is cardiac index, measured by thermodilution
technique. Patients with right heart catheterisation
within 30 days of their CMR were included in analysis of
associations between right heart catheterisation metrics
and myocardial T1.
CMR acquisition
CMR was performed on a whole body 1.5 T scanner
(HDx scanner, GE Healthcare, Waukesha, Wisconsin,
USA), using an 8-channel cardiac coil. Subjects were
scanned in the supine position with electrocardiogram
(ECG) gating. Short axis cine images were acquired
using a multi-slice balanced steady state free precession
(bSSFP) sequence with: temporal phases per cardiac
cycle: 20; field of view: 480 mm; matrix: 256 × 256; band-
width: 125KHz/pixel; TR: 3.7 ms; TE: 1.6 ms.
T1 mapping was performed using a 2D 3–3-5 MOLLI
sequence in a single short axis slice [17]. A bSSFP acqui-
sition was executed at each inversion time point with
the following sequence parameters: Flip angle: 35°; image
dimensions: 128 × 128; TR: 3.20 ms; TE: 1.41 ms; parallel
imaging using sensitivity encoding with acceleration fac-
tor 2; FOV: 400 mm; slice thickness: 5.1 mm.
CMR image analysis
Cine CMR analysis was performed prospectively on
a GE Advantage Workstation 4.1 by a radiographer
with 10 years’ experience, who was blinded to the
patient’s clinical data. Right and left endocardial and
epicardial surfaces were manually traced on the short
axis cine images to obtain the volumetric indices;
RV end diastolic volume (RVEDV), RV end systolic
volume (RVESV), LV end diastolic volume (LVEDV)
and LV end systolic volume (LVESV). From the end
diastolic and end systolic volumes, RV ejection frac-
tion (RVEF) and LV ejection fraction (LVEF) were
calculated. The interventricular septum was included
in the LV mass. RV mass was estimated from the
sum total of the myocardial slice volumes and an
assumed myocardial density of 1.05 g/cm3. Ventricu-
lar mass index was calculated as VMI = RV mass /
LV mass. CMR volume and mass measurements were
indexed for body surface area where appropriate.
Interventricular septal angle was measured by deter-
mining the angle between the mid-point of the inter-
ventricular septum and the RV insertion points at
RV end systole [18].
All MOLLI images were spatially registered to correct
any respiratory or cardiac motion using a Matlab (Math-
works, Natick, Massachusetts, USA)-based non-rigid
image registration algorithm [19], which was integrated
into a Matlab voxelwise T1 mapping algorithm based on
the work by Xue et al. [20]. Analysis of T1 maps was
performed by a Cardiothoracic Radiologist with 7 years
CMR experience, blinded to the patient’s demographic
and clinical data. Regions of interest were drawn on the
interventricular septum, RV insertion points and LV free
wall, see Fig. 2 [21]. A measure of ΔT1RS was used to as-
sess elevation of the T1 in the RV insertion points, nor-
malised to septal T1. Regions of interest were compared
across pulmonary hypertension subtypes (see flowchart
in Fig. 1). All T1 maps were analysed by both the same
observer, and a second observer, who was a trained
CMR researcher with 2 years of experience analysing T1
mapping images blinded to previous results and patient
data for interobserver and intraobserver reproducibility.
Fig. 1 Patient flowchart. Patients were grouped for statistical analysis
as indicated. Patients with pulmonary hypertension were compared
to two control groups. Patients with left heart disease (LHD), pulmonary
arterial hypertension (PAH), PAH due to lung disease and/or hypoxia
(PH-lung), chronic thromboembolic pulmonary hypertension (CTEPH)
and pulmonary hypertension with unclear or multifactorial causes
(PH-misc) were compared using ANOVA. Patients with idiopathic
pulmonary arterial hypertension (IPAH), connective tissue disease (CTD),
congenital heart disease (CHD) and other types of PAH were compared
using ANOVA. Patients with PAH were assessed for independent
prognostic value of T1. Three patients had previous right heart
catheter data showing mean PAP > 25 mmHg but did not have
a final diagnosis, and were included in analysis of pulmonary
hypertension patients
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Follow up period
Patients with PAH were followed up with a census date
of 30.01.2018 with a mean follow-up period of 27 ±
8 months and a median follow-up period of 30 months
from CMR to death or census.
Statistical analysis
Statistical analysis was performed and presented using
SPSS 21 (SPSS, Statistical Package for the Social
Sciences, International Business Machines, Inc.,
Armonk, New York, USA). Data are presented as
mean ± standard deviation. Group comparisons were
made using two-tailed ANOVA; post-hoc Bonferroni
was used for multiple group corrections. Pearson’s
correlation coefficient was used to assess the strength
of correlations. Receiver operating characteristic
(ROC) analysis was employed to assess the diagnostic
accuracy of T1 metrics with area under the curve.
Intra and interobsever variability was assessed using
the intraclass correlation coefficient (ICC); absolute
values and 95% confidence intervals. To control for
the heterogeneity of aetiology and therapy differences
between the different subtypes of pulmonary hyper-
tension, we elected to study the prognostic value of
T1 metrics in patients with PAH alone. This controls
for differences in outcome caused by factors such as
Table 1 Characteristics of subjects
N Patients: PAH Group 3 PH LHD Patients: no PAH Healthy Subjects
369 39 82 24
Demographics and characteristics
Age (years) 58.2 ± 15.0 68.1 ± 12.7** 55.4 ± 18.3 58.1 ± 3.88
Sex (female %) 66.0 59.5 67.1 50.9
Subgroup diagnoses (n) N/A N/A –
Group 1 PAH n = 223
PH-Lung n = 41
CTEPH n = 92
PH-MISC n = 10
BSA (m2) 1.81 ± 250 1.89 ± 0.26 1.85 ± 0.25
CMR
Heart Rate (bpm) 72.17 ± 14.4 69.81 ± 3.8 67.9 ± 10.3**
CMR at incident vs prevalent time (incident %) N = 165 (45%) N = 31 (80%) N = 82 (100%)
RV insertion T1 (ms) 1065 ± 86 1074 ± 10 1017 ± 69 943 ± 52**
Septal T1 (ms) 975 ± 67 986 ± 73 976 ± 75 940 ± 56*
LV free wall T1 (ms) 965 ± 68 982 ± 81 961 ± 66 913 ± 55**
RVEDV Index (ml/m2) 87.2 ± 34.1 81.9 ± 31.7 68.0 ± 20.4**
RVESV Index (ml/m2) 51.7 ± 29.0 45.4 ± 23.1 31.1 ± 11.6**
RVSV Index (%) 35.6 ± 14.2 36.5 ± 12.1 36.9 ± 12.9
RVEF (%) 43.1 ± 13.6 46.8 ± 11.2 54.4 ± 10.0**
LVEDV Index (ml/m2 58.5 ± 16.1 68.9 ± 21.2** 66.6 ± 16.1**
LVESV Index ml/m2) 19.2 ± 8.2 26.1 ± 16.6** 21.3 ± 8.2*
LVSV Index (%) 39.2 ± 11.9 42.8 ± 13.4 45.3 ± 10.8**
LVEF (%) 67.3 ± 9.7 63.8 ± 14.5 68.3 ± 7.6
Systolic septal angle (°) 165.5 ± 23.9 145.9 ± 15.5 150.5 ± 108.4*
Diastolic septal angle (°) 143.34 ± 11.0 138.3 ± 10.3** 134.9 ± 7.9*
RV mass index (g/m2) 21.9 ± 12.5 14.4 ± 5.5** 11.9 ± 5.8*
LV mass index (g/m2) 48.0 ± 12.3 57.2 ± 21.1** 47.7 ± 10.7
VMI (ratio) 0.47 ± 0.27 0.28 ± 0.13** 0.26 ± 0.18*
WHO world health organisation, PAH ipulmonary arterial hypertension, CTEPH chronic thromboembolic pulmonary hypertension, RVEDV right ventricular end
diastolic volume, RVESV right ventricular end systolic volume, RVSV right ventricular stroke volume, RVEF right ventricular ejection fraction, VMI ventricular mass
index, LVEDV left ventricular end diastolic volume, LVESV left ventricular end systolic volume, LVSV left ventricular stroke volume, LVEF left ventricular ejection
fraction, VMI ventricular mass index, CMR cardiovascular magnetic resonance
P values indicate comparisons between patients with PH and the other two groups. * signifies a p value < 0.05, ** signifies a p value < 0.025
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severe lung disease in respiratory patients and chronic
thromboembolic disease in patients undergoing pul-
monary endarterectomy. Log-log plots were produced
for T1 metrics to assess proportional hazards, with
variables dichotomised by median values, and prog-
nostic value was assessed using univariate Cox pro-
portional hazards regression analysis. Variable scaling
(Z-score) was performed to allow direct comparison
of hazard ratios of all continuous variables by sub-
tracting the mean from individual values and dividing
by the standard deviation of the variable. Groups
were compared using the log-rank (Mantel-Cox) test.
Unless otherwise stated, a value of p < 0.05 was con-
sidered statistically significant.
Results
Characteristics of the study populations are given in
Table 1. Additional data on characteristics of PAH
subtypes are given in Additional file 1: Tables S1 and
S2. Patients with PAH were not significantly different
in age or sex than patients without PAH or healthy
subjects. Figure 1 illustrates the classification of the
patients included in the study.
Native myocardial T1 mapping
In patients with PAH, T1 was significantly elevated at
the RV insertion points when compared to healthy sub-
jects and patients without PAH (patients with
pulmonary hypertension, T1 = 1065 ± 86 ms; healthy
subjects, T1 = 943 ± 52 ms, p < 0.001; patients PAH T1 =
1017 ± 69 ms, p < 0.001). Patients with PAH also had ele-
vated T1 in the LV free wall and septum when compared
to healthy subjects but not patients PAH, (patients with
PAH: LV free wall T1 = 975 ± 67 ms, septal T1 = 965 ±
68 ms; patients without PAH: LV free wall T1 = 961 ±
66 ms, septal T1 = 976 ± 75 ms; healthy subjects LV free
wall T1 = 913 ± 55 ms, p < 0.001, septal T1 = 940 ±
56 ms, p = 0.011). See Table 1 and Figs. 2, 3. Patients
with PAH who were undergoing treatment did not have
significantly different T1 to those who were untreated
(septal: p = 0.182; RV insertion point: p = 0.977; LV free
wall: p = 0.46). The standard deviation of T1 s within the
RV insertion points was significantly higher in patients
with PAH (SD = 62.2 ms) compared to healthy subjects
(SD = 36.5 ms). The standard deviation of T1 s within
the LV free wall and septum were not significantly differ-
ent in healthy subjects when compared to patients (sep-
tal: 54.4 ms, LV free wall: 42.9 ms) with PAH (septal:
54.6 ms, LV free wall: 44.6 ms).
Diagnostic accuracy of myocardial T1
The T1 at the RV insertion points was the most statisti-
cally significant measurement for discriminating between
subjects and patients with PAH, followed by ΔT1RS.
However, no T1 region was successful in discriminating
between patients without PAH and patients with PAH,
see Table 2.
Fig. 2 Representative T1 maps. Representative T1 maps in short axis geometry of a) a healthy subject, b) a patient without pulmonary artery
hypertension, c) a patient with idiopathic PAH and d) a patient with left heart diseaes. Demonstrative regions of interest are places on the RV insertion
points, interventricular septum and LV free wall
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T1 changes in pulmonary artery hypertension subtypes
Comparisons were made between PAH subgroups and
there were no significant differences between subgroups.
For PAH patients, LV free wall T1 was significantly
higher (p = 0.046) in patients with CTD than patients
with CHD. There were no other significant differences
between groups, see Fig. 4.
Relationship between T1 and other measures of cardiac
structure and function
Across the population of PAH patients scanned, the RV
insertion point T1 had the strongest relationship with
RV function. The mean insertion point T1 correlated
significantly with RVEDV index, RVESV index and
RVEF. Additionally, the RV insertion point T1 showed
significant correlations with RV mass index, the VMI
and the systolic and diastolic septal angle, see Table 3.
Septal T1 and LV free wall T1 did not correlate with any
of the imaging markers of RV function or LV function.
However, diastolic septal angle and septal T1 showed a
positive correlation (R = 0.152), see Table 3.
A multivariate forward linear regression showed that
RVESVI and systolic septal angle were significant inde-
pendent predictors of RV insertion point T1 in patients
with PAH.
In patients with left heart disease the RV insertion
point T1, septal T1 and LV free wall T1 all showed sig-
nificant correlations with cine CMR metrics of RV func-
tion. ΔT1RS correlated significantly with diastolic and
systolic septal angle in patients with left heart disease,
(see Table 4).
A total of 228/369 patients with PAH, 30/39 patients with
PAH due to left heart disease and 29/82 patients without
PAH also had right heart catheter within 1 month of CMR
scanning (mean of 0 ± 1 days, range 15 days). Mean PAP
for each patient group was as follows: patients with PAH:
44 ± 13; patients with PAH and left heart disease: 40 ± 12;
patients without PAH 19 ± 3. Right heart catheter data is
presented for patient subjects in Additional file 1: Table S3.
The mean RV insertion point T1 correlated signifi-
cantly with the functional parameters mean PAP, mean
right atrial pressure, and CI but not PVR, see Table 5.
There was also a significant correlation with mixed ven-
ous oxygen saturation (SvO2). LV free wall T1 correlated
significantly with CI and SvO2, whilst septal T1 did not
correlate with any of the RHC parameters.
Fig. 3 Mean T1 in patients with pulmonary artery hypertension, patients without pulmonary artery hypertension and healthy subjects. Box plot of
the mean T1 for septal, RV insertion point and LV free wall regions. P values are given for ANOVA comparisons between patients with pulmonary
artery hypertension and control groups above each respective control group. O Represents outliers * represents far outliers
Table 2 ROC curve analysis for distinguishing patients without
PH and patients with PH
Area under
the curve
Lower 95%
Confidence interval
Upper 95%
Confidence interval
RV mass
Index
0.807 0.760 0.855
Systolic
septal angle
0.850 0.809 0.892
Septal T1 0.502 0.426 0.578
RV insertion
point T1
0.654 0.587 0.720
ΔT1RVIP-septum 0.675 0.612 0.738
LV free wall
T1
0.512 0.442 0.582
Legend: ΔT1RVIP-septum = RV insertion point T1 – septal T1
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Patients with left heart disease showed significant cor-
relations between RV insertion point T1 and mean PAP,
mean right atrial pressure, and SvO2. Patients with left
heart disease showed significant correlations with septal
T1 and mPAP as well as SvO2. There were no correla-
tions between LV free wall and right heart catheter
parameters.
Prognostic value of myocardial T1 in PAH
Fifty-nine patients with PAH died during the follow up
period of 29 months (standard deviation: 8 months), of
which 43 had PAH.
Comparison of scaled Cox proportional hazard ratios
are illustrated in Fig. 5. Univariate Cox proportional haz-
ards regression analysis of patients with PAH showed that,
Table 3 Correlations between MR parameters in septal, RV insertion point and LV free wall T1
Septal T1 (ms) RV insertion point T1 (ms) LV free wall T1 (ms)
Age (years) r = − 0.074 p = 0.159 r = 0.007, p = 1.000 r = − 0.086, p = 0.168
BSA (m2) r = 0.015, p = 0.771 r = 0.041, p = 0.444 r = −0.006, p = 0.915
Heart Rate (bpm) r = 0.011, p = 0.836 r = − 0.073, p = 0.168 r = − 0.086, p = 0.103
RVEDV Index (ml/m2) r = 0.066, p = 0.213 r = 0.265**, p < 0.001** r = 0.076, p = 0.151
RVESV Index (ml/m2) r = 0.027, p = 0.615 r = 0.290, p < 0.001** r = 0.088, p = 0.097
RVSV Index (%) r = 0.103, p = 0.050 r = 0.003, p = 0.958 r = 0.044, p = 0.406
RVEF (%) r = 0.003, p = 0.951 r = −0.238, p < 0.001** r = −0.080, p = 0.129
LVEDV Index (ml/m2) r = −0.035, p = 0.505 r = −0.060, p = 0.257 r = − 0.018, p = 0.734
LVESV Index ml/m2) r = 0.005, p = 0.924 r = 0.011, p = 0.841 r = −0.051, p = 0.335
LVSV Index (%) r = 0.051, p = 0.335 r = −0.088, p = 0.096 r = 0.011, p = 0.841
LVEF (%) r = 0.028, p = 0.598 r = −0.066, p = 0.217 r = 0.050, p = 0.347
Systolic septal angle (°) r = 0.096, p = 0.069 r = 0.238, p < 0.001** R = 0.017, p = 0.742
Diastolic septal angle (°) r = 0.157, p = 0.003** r = 0.253, p < 0.001** r = 0.017, p = 0.742
RV mass index (g/m2) r = 0.097, p = 0.075 r = 0.229, p < 0.001** r = 0.004, p = 0.935
LV mass index (g/m2) r = −0.027, p = 0.613 r = 0.072, p = 0.173 r = 0.041, p = 0.435
VMI r = 0.117, p = 0.031* r = 0.180, p = 0.001** r = −0.010, p = 0.851
Legend: WHO world health organisation, IPAH idiopathic pulmonary arterial hypertension, CTD Connective tissue disease, CHD chronic heart disease, CTEPH
chronic thromboembolic pulmonary hypertension, RVEDV right ventricular end diastolic volume, RVESV right ventricular end systolic volume, RVSV right ventricular
stroke volume, RVEF right ventricular ejection fraction, VMI ventricular mass index, LVEDV left ventricular end diastolic volume, LVESV left ventricular end systolic
volume, LVSV left ventricular stroke volume, LVEF left ventricular ejection fraction, VMI ventricular mass index
P values indicate comparisons between patients with PH and the other two groups. * signifies a p value < 0.05, ** signifies a p value < 0.025
Fig. 4 Mean T1 in subgroups of patients with pulmonary hypertension. Box plot of mean T1 for septal, RV insertion point and LV free wall regions for
pulmonary artery hypertension patient subtypes. PAH other includes all patients with PAH who do not have IPAH,CTD or CHD. O Represents outliers *
represents far outliers
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septal, LV free wall and RV insertion point T1 were not
associated with mortality (septal: p = 0.522; LV free wall:
p = 0.258; RV insertion point: p = 0.688), see Table 6.
Reproducibility
T1 values in the septum, RV insertion point and LV free
wall were tested for absolute agreement with a random
two-way model. The intraclass correlation coefficients
for the interventricular septum, RV insertion points and
LV free wall T1 values respectively were: 0.841, 0.823
and 0.792 respectively. The interclass correlation coeffi-
cients for the septum, RV insertion point and LV free
wall T1 values respectively were: 0.844, 0.742 and 0.618
respectively. Reproducibility was found to be excellent in
all regions in healthy subjects, intraclass correlation co-
efficients for the interventricular septum, RV insertion
points and LV free wall T1 values were: 0.898, 0.934 and
0.852 respectively. The interclass correlation coefficients
for the septum, RV insertion point and LV free wall T1
values were: 0.972, 0.942 and 0.824 respectively.
Discussion
Despite the clinical heterogeneity found in subtypes of
PAH in the patients in this study, there were no
significant differences found in myocardial T1 between
the subtypes of this population. In particular, patients
with left heart disease who were considered separately
(due to a different aetiology and cardiac phenotype) were
found to have no significant differences from patients
with other forms of PAH, this may be because the causal
mechanism of T1 differences in PAH be present to some
extent in all PAH subtypes. However, this may also be
due to multiple casual mechanisms causing elevated T1
in PAHdue to the heterogeneity of the disease.
Patients with CTD have been previously found to have
elevated T1 when compared to controls [22], however
we did not find that patients with CTD had significantly
different T1 in any region when compared with patients
with idiopathic PAH. This indicates that any tissue
changes caused by the presence of cardiac connective
tissue were not detectable in this study, likely having a
less significant effect than those of PAH itself, or
patients with connective tissue disease did not have sig-
nificant LV disease.
Two control groups were used to evaluate changes in
the myocardium in patients with PAH: age matched
healthy subjects and patients without PAH. Patients
without PAH had significantly higher RV insertion point
T1 when compared to healthy subjects. Although these
patients do not meet the criteria for PAH diagnosis, they
have a mean PAP of 19.4 ± 2.7, which is higher than seen
in a healthy subject population. Additionally, T1 changes
are not specific to PAH, and therefore raised T1 in this
group may be due to other disease such as connective
tissue disease or left heart disease in this patient
population.
Though both RV insertion point T1 and ΔT1RS were
successful at differentiating healthy subjects from patients
with PAH, they were not successful at differentiating con-
trol patients from patients with PAH. ΔT1RS was not sig-
nificantly different between control groups, which
suggests regional elevation of the insertion point T1 is
characteristic of PAH rather than elevation of the whole
myocardial T1. The lack of specificity of RV insertion
Table 5 Correlations between RHC parameters in septal, RV insertion point and LV free wall T1
RHC data Septal T1 (ms) RV insertion point T1 (ms) LV free wall T1 (ms)
Mean RAP (mmHg) r = 0.074, p = 0.256 r = 0.160, p = 0.011** r = 0.025, p = 0.706
Mean PAP(mmHg) r = 0.076, p = 0.248 r = 0.165, p = 0.011** r = 0.025, p = 0.706
PCWP (mmHg) r = −0.002, p = 0.982 r = −0.053, p = 0.434 r = − 0.032, r = 0.634
PVR (dyne/s/cm3) r = 0.039, p = 0.567 r = 0.099, p = 0.145 r = 0.096, p = 0.160
CI (I/min/m2) r = −0.003, p = 0.964 r = −0.079, p = 0.234 r = − 0.166.p = 0.012**
SvO2 (%) r = −0.004, p = 0.956 r = − 0.152, p = 0.022** r = − 0.168, p = 0.011**
SaO2 (%) r = 0.119, p = 0.070 r = −0.081, p = 0.222 r = − 0.065, p = 0.322
Legend: RAP right arterial pressure, PAP pulmonary artery pressure, PCWP pulmonary capillary wedge pressure, PVR pulmonary vascular resistance, CI cardiac
index, SvO2 venous oxygen saturation, SaO2 arterial oxygen saturation
P values indicate comparisons between patients with PH and the other two groups. * signifies a p value < 0.05, ** signifies a p value < 0.025
Table 4 Linear regression analysis for RV insertion point T1
Unstandardized
Coefficients
Standardized
Coefficients
t p-value
B Std.
Error
Beta
Constant .845 .073 11.609 < 0.001
RVESVI .000623 0.000247 .209 2.524 0.008
RVEF −0.000213 0.000500 −.034 −.425 0.921
VMI .001 .001 .119 1.483 0.837
Septal angle
systolic
.001 .000 .178 2.918 0.004
Relative Area
Change
−.001 .001 −.066 −.755 0.655
Legend: RVESVI right ventricular end systolic index, RVEF right ventricular
ejection fraction, VMI ventricular mass index
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point T1 indicates that processes responsible for the ele-
vated RV insertion point T1 are not solely confined to
patients with PAH.
The RV insertion points were the myocardial regions
with the highest T1 and they correlated significantly
with loss of RV function and RV remodelling. Systolic
septal angle and RVESVI were independent predictors of
RV insertion point T1, however these variables only pre-
dicted 12.4% of the variance seen in RV insertion point
T1 in patients with PAH. This may indicate that
mechanisms which are not explicable solely through car-
diac volume, mass and pressure changes are responsible
for the tissue changes represented by T1.
Animal models of PAH with increased native T1 and
LGE present in the RV insertion points have been
shown to have increased interstitial collagen associated
with fibre disarray, and increased connective tissue
density [11]. It has been shown in two patients with
PAH that fibrosis was present in the RV insertion point
and it has been suggested that this is the mechanism
Table 6 Cox linear regression analysis for RV insertion point T1 in PAH. All variables have been normalised
Univariate Hazard Ratio Univariate 95% confidence interval Univariate P Value
Age 1.938 1.342–2.798 < 0.001**
Sex 0.765 0.573–1.021 0.077
Septal T1 0.909 0.661–1.249 0.552
RV insertion point T1 1.067 0.778–1.464 0.688
LV free wall T1 1.195 0.879–1.624 0.258
ΔT1RS 1.205 0.888–1.634 0.237
RVEDVI 1.642 1.330–2.027 < 0.001**
RVESVI 1.804 1.453–2.240 < 0.001**
RVEF 0.506 0.372–0.690 < 0.001**
Systolic septal angle 1.454 1.093–1.934 0.011**
Diastolic septal angle 1.485 1.099–2.008 0.011**
RV mass Index 1.341 1.091–1.649 0.018**
Legend: RVEDVI right ventricular end diastolic volume index, RVESVI right ventricular end systolic volume index, RVEF right ventricular ejection fraction
Fig. 5 Forest Plot of hazard ratios for patient demographics and CMR derived metrics. RVEDV: right ventricular end diastolic volume. RVESV: right
ventricular end systolic volume. RVSV: right ventricular stroke volume. RVEF: right ventricular ejection fraction. VMI: ventricular mass index. LVEDV:
left ventricular end diastolic volume. LVESV: left ventricular end systolic volume. LVSV: left ventricular stroke volume. LVEF: left ventricular ejection
fraction. VMI: ventricular mass index
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driving LGE in PAH [23]. However, those patients also
had an increase in interstitial space and a small increase of
fat. A CMR case study of one patient with idiopoathic
PAH showed myocardial disarray with increased collagen
and fat between fibre bundles in the myocardium (plexi-
form fibrosis). That study suggests that the cause of LGE
is not pathological, and instead arises from an exagger-
ation of the myocardial disarray and plexiform fibrosis
where fibres from the RV and LV cross. It is suggested this
exaggeration of myocardial disarray may arise from a
combination of RV hypertrophy and increased shear
forces upon the interventricular septum [24].
Interventricular septal angle is a measure of deviation
of the LV septum due to the high pressure in the RV,
which correlated strongly with RV insertion point T1 in
patients with PAH and was found to be an independent
linear predictor of RV insertion point T1. Even in
patients with left heart disease, who do not exhibit diver-
gence of the LV septum to the same degree as other
patients with PAH, ΔT1RS correlated significantly with
septal angle. The T1 value of the LV free wall, which
would not experience stress/strain due to elevated ven-
tricular pressure, was found to show no correlation
between T1 and septal angle and was not elevated in
patients with PAH when compared to patients without
PAH. Therefore, our data suggests that the regional ele-
vated native T1 in the insertion points is significantly
related to the displacement of the interventricular
septum in PAH. This supports the suggestions from
histological studies that changes in myocardial T1 and the
presence of LGE may be due to exaggerated fibre disarray
in the RV insertion points of the myocardium due to
stress on the septum and RV insertion points in PAH.
RV insertion point T1 was not an independent significant
predictor of mortality in patients with PAH. Although LGE
and elevated native T1 has been observed in the interven-
tricular septum in PAH [3–5], elevated native T1 was not
observed in this study. This may be because regions of
interest were placed in the middle of the interventricular
septum, whereas LGE imaging shows myocardial changes
extending from the insertion points and therefore weakest
enhancement at the central region of the septum.
Reproducibility data was found to be in line with that
previously observed in patient T1 mapping studies [24].
The RV insertion points were found to be less reprodu-
cible than the interventricular septum. This may be due
to higher T1 heterogeneity in this region leading to
greater T1 variation when region of interest placement
differs. T1 values tended to be less reproducible in
patients with PAH than healthy subjects, which is con-
sistent with other studies findings [24]. It may be that
relatively poor breath-holding of the patient cohort con-
tributes a greater degree of motion artefact resulting in
weaker reproducibility.
Myocardial T1 did not provide additive diagnostic
or prognostic information in this PAH cohort. It
may be that myocardial changes are a secondary
effect of cardiac remodelling and are therefore less
relevant in this disease. However, it may also be that
traditional region of interest based analysis of T1 is
less suitable for this patient population due to het-
erogeneous T1 across the myocardium resulting in
weaker reproducibility.
In conclusion, the RV insertion points have been
shown to be the region where T1 changes are most sig-
nificantly related to cardiac function in PAH. Myocardial
T1 did not differ significantly between PAH subtypes
including LHD. The T1 in the RV insertion point was
significantly associated with RV volume and function in
the patients scanned. Interventricular septal angle inde-
pendently predicted RV insertion point T1 in patients
with PAH suggesting that regional elevation in the RV
insertion point may be linked to increased stress on the
interventricular septal wall. T1 in patients with PAH was
not found to be prognostic independent of RV size and
function. Overall, T1 mapping does not appear to pre-
dict the subtype of PAH, or provide additive value over
RV volume, mass and geometry in the prognostic evalu-
ation of patients with PAH.
Limitations
It is a limitation of this study that concurrent right heart
catheter and CMR data were not present for all subjects.
The follow up period for this study was relatively short,
with 85% of patients alive at the follow-up date. There-
fore, census at a later point may be required to provide
more definitive evidence of whether RV insertion point
T1 has independent prognostic value. Further work to
evaluate regions of interest at the inferior and superior por-
tions of the interventricular septum may clarify whether
septal changes are present in these regions. The relation-
ship between T1 and LGE in the RV insertion points was
not evaluated here and further work may be warranted to
evaluate this thoroughly in patients with PAH.
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